New Software Module Slashes Time Required to Complete Reporting Phase of Preclinical Studies

Share Article

Time-to-market greatly reduced through the use of preclinical software vendor’s newest module, ReportBase(tm). The new integrated module slashes time needed to complete preclinical FDA-compliant final reports.

Preclinical software vendor PDS Pathology Data Systems, Ltd. announced the release of their newest module, ReportBase(tm). In making the announcement, company CEO Bruno Eschbach stated, “For many years, PathData(r) System users have enjoyed one of the industry’s most advanced and flexible system-integrated reporting tools. We are very proud to say our new reporting module, ReportBase(tm), provides a quantum leap to the most ultra-modern and cutting edge scientific reporting capabilities for our entire product suite, including the PathData(r) System for macro and histopathology, the ToxData(r) System for general toxicology and clinical pathology, and the ReproData(r) System for reproduction toxicology and teratology.”

“There are several key factors to the ReportBase(tm) module’s innovations,” explained Reto Aerni, the company’s Technical Director for the In-Life projects. “We have continued our policy of doing what is best for our users, not what is easiest for us. That includes being independent of any third-party software so that users are not burdened with the significant costs related to adaptations to third-party software release changes and their resulting validation efforts. Third-party software life cycles are troublesome in validated environments. Our users tell us they are grateful to not have to deal with those issues. Also important is the ability for our users to easily customize their reports using flexible layout and structure templates and create reports that conform to their own corporate standards. Now CROs can very easily maintain templates that cover the wide and varied needs of their sponsors. Even external information such as specialized clinical pathology results, water quality analysis, images and more can be brought into the report.”

Aerni went on the explain, “A two-year study takes two years to run. There is no way around that. ReportBase(tm), with its ability to support multiple authors contributing various components and the effortless hyperlinking of narratives to tabulated data points, along with may other features, slashes the time it takes for completing FDA-compliant final reports by as much as eighty percent. This means significant savings for our users and for the sponsors of the studies. The scientific reports are completed with true rapidity and less resources. This results in fewer errors and expedites time-to-market for new products. That, in turn, frees up staff to allow them to bring even more value to the organization.”

About the company- PDS Pathology Data Systems, Ltd. is a leading provider of preclinical software solutions for over twenty-five years. PDS consistently develops innovative products such as PathData(r), ToxData(r), and ReproData(r). The software systems are designed by experts for experts, with high priority placed on the integration of evolving user and regulatory requirements.

As an alternative to traditional software licensing, PDS was the first preclinical software vendor to make its software available as a fully hosted and subscription-based solution. The main advantage of the hosted solution is that it requires no up-front investment and users can ‘pay-as-they-go’ to access the same world-class software that is used by eighty percent of the top-ten pharmaceutical companies worldwide.

PDS is an exhibitor at the Society of Toxicology conference in San Diego, CA March 5-8, 2006, booth 719.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Arthur Karakos, CEO
Visit website